IL4R and conjunctivitis: Despite these limitations, our research has shed light upon the potential pathomechanism of conjunctivitis in AD trials by identifying anti–IL-4Rα-augmented genes that could account for partial efficacy of IL4Ra blockade on murine conjunctivitis, as well as candidate markers for conjunctivitis clinically.